SYNTELLO AB has a total of 17 patent applications. Its first patent ever was published in 1987. It filed its patents most often in Canada, Norway and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are HEBEI YILING MEDICINE INST CO, VIROVAHL SA and MEDIGENE IMMUNOTHERAPIES GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 5 | |
#2 | Norway | 3 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | Sweden | 2 | |
#5 | Australia | 1 | |
#6 | Finland | 1 | |
#7 | Hungary | 1 | |
#8 | New Zealand | 1 | |
#9 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Machines |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Microorganisms | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Horal Peter | 15 |
#2 | Rymo Lars | 15 |
#3 | Svennerholm Bo | 15 |
#4 | Vahlne Anders | 14 |
#5 | Jeansson Stig | 14 |
#6 | Vahlne A | 2 |
#7 | Jeannsson Stig | 1 |
Publication | Filing date | Title |
---|---|---|
CA1338001C | Synthetic peptide antigens for the detection of htlv-1 infection | |
CA1338028C | Synthetic peptide antigens for the detection of hiv-1 infection | |
HU906639D0 | And treating htlv-1 peptides and antibodies against them for diagnosting htlv-1 infection and for vaccination against it | |
US5283320A | Peptides for HTLV-2 infection diagnosis of, therapy for, vaccination against, for distinguishing between HTLV-1 and HTLV-2 infections and antibodies derived therefrom | |
SE8701294D0 | HIV-1 gp41 peptide, vaccine and antigen containing the peptide and also diagnostic test using the peptide |